---
anonymous_label: OUT-14
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 4a3d2cf9f80fbd4d9decdcb14fdfa13e9ce2650a85a9de0baf0f7b0cb77e6994
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-14

I recommend that you commit to the **Case Evidence Review**.

### Reasoning and Tradeoffs

You are currently facing a "false positive" signal. Your financial metrics (expansion bookings, shortened cycles) are being driven by **sales incentives** (bundle pricing/fiscal year-end pressure) and **roadmap promises**, not necessarily by the inherent value of the product.

The usage data is equally deceptive. A 39% increase in activity is meaningless if it is driven by managers "practicing" on closed cases rather than analysts solving live problems. The most alarming signal is the public-sector abandonment: if an analyst cannot explain a recommendation to their reviewer, the product isn't a tool—it's a liability.

Here is why I rejected the other options:
*   **Scale PlanPilot broadly:** This is reckless. You have early indicators of churn (the regional administrators) and a lack of "explainability." Scaling now would likely accelerate churn once the bundle pricing expires.
*   **Adoption Quality Sprint:** This measures *behavior*, not *value*. You already know analysts fall back to manual notes. Tracking that they are doing it more or less frequently doesn't tell you *why* the product is failing to stick.
*   **Demand Cleanroom:** This provides a clean commercial signal, but it is too late for that. You already have the evidence that sales can "sell" the vision; you now need to know if the product can actually "deliver" the value.
*   **Narrow to Public Sector:** This is a premature pivot based on one segment's struggle. You don't yet know if the public sector is a "bad fit" or if the product simply lacks a critical "explainability" feature.

**The Case Evidence Review is the only option that attacks the core uncertainty: Is PlanPilot actually solving the problem, or is it just a sophisticated draft that analysts eventually rewrite by hand?** By auditing whether suggestions were accepted, overridden, or impossible to explain, you move from "proxy metrics" (clicks/bookings) to "ground truth" (utility).

### The Modification
I recommend modifying the Case Evidence Review to include a **specific "Explainability Audit"** for public-sector cases. This displaces the general Case Evidence Review by narrowing the sample set to include a disproportionate amount of public-sector data.
*   **What you give up:** You sacrifice a statistically representative sample of your entire customer base in exchange for deep-dive qualitative data on your most fragile segment.

### The Strongest Reason Against This Recommendation
The Case Evidence Review is slow, manual, and qualitative. It provides "small data" at a moment when the board and CEO are intoxicated by "big data" (16% expansion, 39% usage). By choosing this path, you are choosing to potentially "kill the mood" of a winning quarter with nuanced reports about manual overrides, which may be perceived by executive leadership as "product perfectionism" rather than commercial risk management.

### Evidence That Would Change My Mind
I would shift my recommendation to the **Demand Cleanroom** if you discovered that the regional administrators who are removing PlanPilot from their contracts are doing so specifically because of **price**, not because of **utility**.

If the churn is purely a pricing misalignment, then your problem is a Sales/Packaging problem (which the Cleanroom solves). But if the churn is because the tool doesn't actually save them time or effort, you have a Product problem—and only the Case Evidence Review can tell you how to fix it.
